Haniffa, Muzlifah https://orcid.org/0000-0002-3927-2084
Taylor, Deanne https://orcid.org/0000-0002-3302-4610
Linnarsson, Sten https://orcid.org/0000-0002-3491-3444
Aronow, Bruce J. https://orcid.org/0000-0001-5109-6514
Bader, Gary D. https://orcid.org/0000-0003-0185-8861
Barker, Roger A.
Camara, Pablo G.
Camp, J. Gray https://orcid.org/0000-0003-3295-1225
Chédotal, Alain https://orcid.org/0000-0001-7577-3794
Copp, Andrew https://orcid.org/0000-0002-2544-9117
Etchevers, Heather C. https://orcid.org/0000-0003-0201-3799
Giacobini, Paolo https://orcid.org/0000-0002-3075-1441
Göttgens, Berthold https://orcid.org/0000-0001-6302-5705
Guo, Guoji https://orcid.org/0000-0002-1716-4621
Hupalowska, Ania
James, Kylie R.
Kirby, Emily
Kriegstein, Arnold https://orcid.org/0000-0001-5742-2990
Lundeberg, Joakim https://orcid.org/0000-0003-4313-1601
Marioni, John C. https://orcid.org/0000-0001-9092-0852
Meyer, Kerstin B. https://orcid.org/0000-0001-5906-1498
Niakan, Kathy K. https://orcid.org/0000-0003-1646-4734
Nilsson, Mats https://orcid.org/0000-0001-9985-0387
Olabi, Bayanne
Pe’er, Dana https://orcid.org/0000-0002-9259-8817
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Rood, Jennifer
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Satija, Rahul https://orcid.org/0000-0001-9448-8833
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Treutlein, Barbara https://orcid.org/0000-0002-3299-5597
Vento-Tormo, Roser https://orcid.org/0000-0002-9870-8474
Webb, Simone https://orcid.org/0000-0003-3058-8952
,
Barbry, Pascal
Bayraktar, Omer
Behjati, Sam
Bosio, Andreas
Canque, Bruno
Chalmel, Frédéric
Gitton, Yorick
Henderson, Deborah
Jorgensen, Anne
Lisgo, Steven
Liu, Jinyue
Lundberg, Emma
Maitre, Jean-Léon
Mazaud-Guittot, Séverine
Robertson, Elizabeth
Rolland, Antoine
Scharfmann, Raphael
Souyri, Michèle
Sundström, Erik
Zaffran, Stéphane
Zilbauer, Matthias
Article History
Received: 8 September 2020
Accepted: 7 May 2021
First Online: 8 September 2021
Competing interests
: A. Regev is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was a Scientific Advisory Board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. From 1 August 2020, A. Regev and O.R-R. are employees of Genentech. S.A.T. has consulted for Genentech and Roche, and is a remunerated member of Scientific Advisory Boards for GlaxoSmithKline, Biogen and Foresite Labs. J. Lundeberg is a scientific advisor for 10x Genomics. All other authors declare no competing interests.